Researchers reported ErbB-OSV, an engineered vesicular stomatitis virus variant designed to selectively target metastatic ovarian cancer while sparing normal tissue. The study describes a mechanism and efficacy profile that the team claims is stronger than the attenuated VSV-ON-∆M51 strain used in prior work. The program targets a key barrier for oncolytic virotherapy—achieving tumor-selective killing with an acceptable safety profile—by using engineered targeting and potency enhancements. If validated in further studies, the approach could broaden the competitive set of viral platforms focused on metastasis-specific disease biology.